{"analyses":[{"ciLowerLimit":"-2.54","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.03","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.16","estimateComment":"Treatment difference at Cycle 5","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"LS Mean difference","paramValue":"-0.26"},{"ciLowerLimit":"-3.24","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.28","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.40","estimateComment":"Treatment difference at Cycle 12","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"LS Mean difference","paramValue":"-0.48"},{"ciLowerLimit":"-1.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.58","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.59","estimateComment":"Treatment difference at safety follow-up","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"LS Mean difference","paramValue":"1.44"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.78","value":"75.73"},{"groupId":"OG001","spread":"1.76","value":"75.47"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.40","value":"78.39"},{"groupId":"OG001","spread":"2.40","value":"77.91"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"122"}],"units":"Participants"}],"title":"Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.58","value":"74.55"},{"groupId":"OG001","spread":"2.49","value":"75.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"134"}],"units":"Participants"}],"title":"Safety follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"description":"The CTSQ measures treatment satisfaction in individuals with cancer and includes a domain for satisfaction with therapy. The satisfaction with therapy scores ranges from 0 to 100 points, with 100 points indicating greatest satisfaction.\n\nAnalysis was based on ANCOVA model. The dependent variable of the models were the scale scores measured at each visit. The model included effects of intercept, scale score measured at cycle 2 day 1 visit, treatment arm, and randomization stratification factors.","dispersionType":"Standard Error","groups":[{"description":"Carfilzomib was administered twice-weekly intravenously as a 10 ± 5 minute infusion using an infusion pump on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. The dose was 20 mg/m\\^2 on Days 1 and 2 of Cycle 1 and 27 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"OG000","title":"Twice-weekly KRd 20/27 mg/m^2"},{"description":"Carfilzomib was administered once-weekly intravenously as a 30 ± 5 minute infusion using an infusion pump on Days 1, 8, and 15 of each 28-day cycle. The dose was 20 mg/m\\^2 on Day 1 of Cycle 1 and 56 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"OG001","title":"Once-weekly KRd 20/56 mg/m^2"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The ITT population included all randomized participants. Participants with data available at each time point are presented.","reportingStatus":"POSTED","timeFrame":"Cycle 5 Day 1, Cycle 12 Day 1, and safety follow-up (30 days after last dose)","title":"Patient-reported Treatment Satisfaction as Measured by the Cancer Therapy Satisfaction Questionnaire (CTSQ)","type":"SECONDARY","unitOfMeasure":"Score on a scale"}